VIR-7831

From Aaushi
Jump to navigation Jump to search

Indications

Contraindications

  • not yet FDA-approved

Dosage

Mechanism of action

Notes

  • GlaxoSmithKline and Vir Biotechnology are seeking emergency use authorization
  • trial was stopped early "due to evidence of profound efficacy"

More general terms

References

  1. 1.0 1.1 GSK News Release. Mearch 26, 2021 GSK and Vir Biotechnology announce submission of Emergency Use Authorization request to FDA for VIR-7831 for the early treatment of COVID-19. https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-submission-of-emergency-use-authorization-request-to-fda-for-vir-7831-for-the-early-treatment-of-covid-19/
  2. Reuters Staff GSK and Vir Seek Emergency Use of COVID-19 Therapy in United States. Medscape - Mar 26, 2021. https://www.medscape.com/viewarticle/948182